Your browser doesn't support javascript.
loading
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela, Stanislav; Khirsariya, Prashant; van Weerden, Wytske M; Fedr, Radek; Suchánková, Tereza; Búzová, Diana; Cervený, Jan; Hampl, Ales; Puhr, Martin; Watson, William R; Culig, Zoran; Krejcí, Lumír; Paruch, Kamil; Soucek, Karel.
Afiliação
  • Drápela S; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
  • Khirsariya P; International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Czech Republic.
  • van Weerden WM; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Fedr R; International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Czech Republic.
  • Suchánková T; Department of Chemistry, CZ Openscreen, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Búzová D; Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Cervený J; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
  • Hampl A; International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Czech Republic.
  • Puhr M; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
  • Watson WR; International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Czech Republic.
  • Culig Z; Department of Adaptive Biotechnologies, Global Change Research Institute of the Czech Academy of Sciences, Brno, Czech Republic.
  • Krejcí L; Department of Adaptive Biotechnologies, Global Change Research Institute of the Czech Academy of Sciences, Brno, Czech Republic.
  • Paruch K; International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital in Brno, Czech Republic.
  • Soucek K; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Mol Oncol ; 14(10): 2487-2503, 2020 10.
Article em En | MEDLINE | ID: mdl-32579780
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Neoplasias da Próstata / Pirazóis / Pirimidinas / Resistencia a Medicamentos Antineoplásicos / Desoxicitidina / Quinase 1 do Ponto de Checagem / Docetaxel / Mitose Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Neoplasias da Próstata / Pirazóis / Pirimidinas / Resistencia a Medicamentos Antineoplásicos / Desoxicitidina / Quinase 1 do Ponto de Checagem / Docetaxel / Mitose Idioma: En Ano de publicação: 2020 Tipo de documento: Article